Rigel Pharmaceuticals (NASDAQ:RIGL) price on Friday, April 19, rose 2.86% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.08.
A look at the stock’s price movement, the close in the last trading session was $1.05. The beta value (5-Year monthly) was 0.98. Turning to its 52-week performance, $1.96 and $0.71 were the 52-week high and 52-week low respectively. Overall, RIGL moved -23.94% over the past month.
Rigel Pharmaceuticals’s market cap currently stands at around $189.41 million, with investors looking forward to this quarter’s earnings report slated for Apr 30, 2024 – May 06, 2024.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that RIGL is a 50% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
RIGL’s current price about -16.57% and -18.86% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 29.77, while 7-day volatility ratio is 5.87% and 6.11% in the 30-day chart. Further, Rigel Pharmaceuticals (RIGL) has a beta value of 1.06, and an average true range (ATR) of 0.08.
If we refocus on Rigel Pharmaceuticals (NASDAQ:RIGL), historical trading data shows that trading volumes averaged 1.31 million over the past 3 months. The company’s latest data on shares outstanding shows there are 174.83 million shares.
The 1.96% of Rigel Pharmaceuticals’s shares are in the hands of company insiders while institutional holders own 60.97% of the company’s shares. Current price change has pushed the stock -25.52% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RIGL stock continues to rise going into the next quarter.
